OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
April 29, 2026 – OSR Holdings, Inc. (NASDAQ:OSRH) announced that it has entered into a definitive global exclusive license agreement with BCM Europe AG for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2.
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
March 23, 2026 – OSR Holdings, Inc. (NASDAQ:OSRH) announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
January 16, 2026 – Vaximm AG, a subsidiary of OSR Holdings (NASDAQ: OSRH), Inc. and a pioneer in oral T-cell immunotherapies for cancer, announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm’s leadership with deep, long-standing expertise in the company’s core technology.
Vaximm Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
January 12, 2026 – OSR Holdings, Inc. (NASDAQ: OSRH) announced that its subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG for a global exclusive license for its lead immunotherapy candidate, VXM01. Per the agreement, BCM Europe intends to establish and manage a dedicated investment vehicle, which would act as the formal Licensee.
Vaximm Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
December 2, 2025 – OSR Holdings, Inc. (NASDAQ: OSRH) provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG. The parties have agreed to shorten the exclusivity period from six months to three months, reflecting the strong alignment and confidence between Vaximm and BCME in advancing a definitive exclusive global licensing agreement for VXM01.
Vaximm Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones
November 21, 2025 – OSR Holdings, Inc. (NASDAQ: OSRH) announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG, a Swiss-based life sciences investment group and OSRH’s largest shareholder, to explore a potential exclusive global licensing agreement for VXM01, Vaximm’s first-in-class oral cancer immunotherapy platform.
OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm
November 21, 2025 – OSR Holdings, Inc. (NASDAQ: OSRH) announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG’s Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Under Dr. Niethammer’s leadership, Vaximm will focus on integrating its anti-angiogenic immune activation platform with complementary viral oncolysis technologies that have already achieved clinical proof-of-concept (PoC) in a completed U.S. FDA Phase 2a study, through a forthcoming strategic collaboration to be announced in the coming months.
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
July 15, 2025 – OSR Holdings, Inc. (NASDAQ: OSRH) announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2.
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
March 26, 2025 –Vaximm AG, a subsidiary of OSR Holdings, Inc., announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01 in combination with PD-L1 inhibitor in patients with recurrent glioblastoma.